Mentioned:
A publicly traded company on the Nasdaq wants to develop breakthrough new drugs for longevity. And now, they’re partnering up with a biobank in Norway to do it.
What’s happening:
- BioAge Labs (NASDAQ: BIOA) has formed a new collaboration with Norway based HUNT Biobank to analyze 17,000 individual samples to develop new therapeutics for longevity
Why it matters:
- The new deal with HUNT Biobank will give BioAge Labs exclusive drug discovery rights and enable them to develop entirely new types of therapeutics that are specifically focused on treating individuals with cardiometabolic diseases and severe cognitive decline
Going deeper:
- BioAge Labs will leverage artificial intelligence models and machine learning to analyze HUNT Biobank’s proprietary data to identify molecular profiles with disease onset and develop new insights into anti-aging therapeutics
- HUNT Biobank is widely considered to be one of the world’s most prominent biobanks, with biological material from more than a hundred thousand people that includes samples of blood, RNA, DNA and saliva which have been collected over nearly four decades
